November 27, 2025 — Leads & Copy — HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) will present new and updated data from several studies of its discovered compounds at the European Society for Medical Oncology (ESMO) Asia Congress 2025 in Singapore (December 5-7) and the American Society of Hematology (ASH) Annual Meeting in Orlando, USA (December 6-9).
The ESMO Asia Congress 2025 will feature results from a first-in-human study of the anti-CD47 monoclonal antibody HMPL-A83 in advanced solid tumors, and results from the phase II part of the FRUSICA-2 registration study of fruquintinib and sintilimab combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma. Results from the phase II part of the phase II/III study of surufatinib combined with camrelizumab and chemotherapy as a first-line treatment for metastatic pancreatic cancer will also be reported.
Ye Guo (Shanghai, China) will present data from a first-in-human, dose escalation study of HMPL-A83 (A83), an anti-CD47 monoclonal antibody (mAb) in patients with advanced solid tumors during a mini oral session on December 7, 2025, at 11:40 – 11:45 SGT in Hall 407.
Shanshan Wang (Shanghai, China) will present results from the phase 2 part of FRUSICA-2, a study on fruquintinib monotherapy as a second-line treatment in locally advanced or metastatic renal cell carcinoma (RCC) in a proffered paper session on December 5, 2025, at 14:55 – 15:05 SGT in Hall 402.
Shukui Qin (Nanjing, China) will present results from the phase 2 part of a randomized, open-label, active-controlled, phase 2/3 study on surufatinib in combination with camrelizumab, nab-paclitaxel and gemcitabine as the first-line treatment in metastatic pancreatic cancer during a poster display session.
Several poster presentations will cover additional research:
- Se-Hoon Lee (Seoul, Korea) will present data on osimertinib (osi) + savolitinib (savo) in EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) with MET overexpression and/or amplification (OverExp/Amp) following progressive disease (PD) on osi: SAVANNAH Asian subset.
- Yongfeng Yu (Shanghai, China) will discuss patient-relevant outcomes (PROs) from SACHI, a Phase 3 Trial of Savolitinib (Savo) plus Osimertinib (Osi) versus Chemotherapy (Chemo) in EGFR-mutant (EGFRm) and MET-amplified (METamp) Advanced NSCLC after Progression on EGFR-TKIs.
- Longhua Sun (Nanchang, China) will present an analysis of MET Amplification (METamp) with FISH and NGS Method in SACHI Trial.
- Haiyan Yang (Changsha, China) will share research on progression patterns in patients with EGFR-mutant (EGFRm), MET-amplified (METamp) advanced NSCLC treated with savolitinib plus osimertinib.
- Julia Rotow (Boston, US) will present final analysis of MET testing and treatment sequencing after progression of disease on first-line osimertinib in patients with EGFRm advanced NSCLC and acquired MET overexpression and/or amplification: Final analysis of a global real-world study.
- Chen Zhang/ Yi Wang (Ningbo, China) will present preliminary results from a prospective Phase II Trial on fruquintinib combined with TAS-102 with or without SBRT as Third- or Later-Line Treatment in Metastatic Colorectal Cancer.
- Guanghai Dai/ Miaomiao Gou (Beijing, China) will discuss the efficacy and safety of fruquintinib combined with PD-1 inhibitor and chidamide in MSS mCRC: a comparison with real-world bevacizumab plus anti-pd-1 and chidamide arm.
- Zhenyang Liu/ Xiaolin Yang (Changsha, China) will discuss the efficacy and safety of Fruquintinib plus FOLFIRI as Second-line Treatment in Bevacizumab-pretreated RAS-mutated Metastatic Colorectal Cancer.
- Xiujuan Qu/ Lin Xu (Shenyang, China) will share a Real-world Observational Study of Fruquintinib in Combination with Irinotecan and Capecitabine as Second-line Treatment in Patients with Advanced Colorectal Cancer.
- Jianming Xu (Beijing, China) will share a matching-adjusted indirect comparison of Surufatinib versus High-Dose Octreotide LAR in Advanced Extrapancreatic Neuroendocrine Tumors.
- Xubao Liu/ Ziyao Wang (Chengdu, China) will provide data updates from a prospective, open-label study on the efficacy and safety of surufatinib in combination with CAPTEM as conversion therapy in patients with unresectable pancreatic neuroendocrine tumors (pNETs).
The 2025 ASH Annual Meeting will feature a final analysis of long-term results of sovleplenib’s ESLIM-01 China Phase III study in adult patients with chronic primary immune thrombocytopenia. Renchi Yang (Tianjin, China) will present this data during an oral abstract session on December 8, 2025, at 15:15 – 15:30 EST in Room OCCC – W304EFGH.
Fruquintinib is a selective oral inhibitor of all three vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3. It is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.
HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody that exhibits high affinity for CD47. It blocks CD47 binding to Signal regulatory protein (SIRP) α and disrupts the “do not eat me” signal that cancer cells use to shield themselves from the immune system. HUTCHMED currently retains all rights to HMPL-A83 worldwide.
Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations, gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®.
Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA®. HUTCHMED currently retains all rights to surufatinib worldwide.
Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk. Syk is a major component in B-cell receptor and Fc receptor signaling and is an established target for the treatment of multiple subtypes of B-cell lymphomas and autoimmune disorders. HUTCHMED currently retains all rights to sovleplenib worldwide.
Investor Enquiries: +852 2121 8200 / ir@hutch-med.com
Media Enquiries:
FTI Consulting – +44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper
+44 7771 913 902 (Mobile) / +44 7421 898 348 (Mobile)
Brunswick – Zhou Yi
+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
Panmure Liberum
Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden
+44 20 7886 2500
Cavendish
Joint Broker
Geoff Nash / Nigel Birks
+44 20 7220 0500
Deutsche Numis
Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith
+44 20 7260 1000
